These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 27363650

  • 1. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
    Anwar MA, Murad F, Dawson E, Abd Elmageed ZY, Tsumagari K, Kandil E.
    J Surg Res; 2016 Jun 15; 203(2):407-15. PubMed ID: 27363650
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
    O'Brien O, Lyons T, Murphy S, Feeley L, Power D, Heffron CCBB.
    J Clin Pathol; 2017 Nov 15; 70(11):935-940. PubMed ID: 28424234
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA.
    Histopathology; 2016 Oct 15; 69(4):680-6. PubMed ID: 27151331
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
    Nielsen LB, Dabrosin N, Sloth K, Bønnelykke-Behrndtz ML, Steiniche T, Lade-Keller J.
    Histopathology; 2018 Apr 15; 72(5):814-825. PubMed ID: 29119584
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A comparison of immunohistochemical and molecular methods used for analyzing the BRAF V600E gene mutation in malignant melanoma in Taiwan.
    Huang WK, Kuo TT, Wu CE, Cheng HY, Hsieh CH, Hsieh JJ, Shen YC, Hou MM, Hsu T, Chang JW.
    Asia Pac J Clin Oncol; 2016 Dec 15; 12(4):403-408. PubMed ID: 27488807
    [Abstract] [Full Text] [Related]

  • 15. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J, Zhang J, Lu J, Gao J, Lu T, Ren X, Duan H, Liang Z.
    Int J Clin Exp Pathol; 2015 Dec 15; 8(11):15072-8. PubMed ID: 26823846
    [Abstract] [Full Text] [Related]

  • 16. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.
    Pyo JS, Sohn JH, Kang G.
    Endocr Pathol; 2015 Sep 15; 26(3):211-7. PubMed ID: 25957797
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
    Yaman B, Kandiloğlu G, Akalin T.
    Am J Dermatopathol; 2016 Feb 15; 38(2):113-20. PubMed ID: 26630683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.